Research expenses for the third quarter were reported as more than $1 million, significantly higher than the $325,000 reported during the third quarter of 2010. General and administrative expense also more than doubled from the third quarter of 2010 to include nearly $1.2 million in the third quarter of 2011.
During the third quarter, the company submitted an IDE and are awaiting FDA clearance to begin a human clinical study with the company’s proprietary biopolymer scaffolding device for acute spinal cord injury. The company also appointed a medical director and chief scientific officer and expanded the neuroscience team to include a laboratory director and research and development manager.
Related Articles on Orthopedic Device Companies:
Alphatec Spine Names Frances Harrison to Vice President Position
TranS1 Launches Lateral Access Spinal System
K2M Debuts New Cervical Plate System With Blue Ridge Technology
